• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FULC alert in real time by email
    SC 13G/A 1 p24-3193sc13ga.htm FULCRUM THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 5)*
     

    Fulcrum Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    359616109

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 359616109SC 13G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 359616109SC 13G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    - 0 -

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 359616109SC 13G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Fulcrum Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 26 Landsdowne Street, Cambridge, Massachusetts 02139.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) that were directly held by the RTW Funds; and

     

      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares that were directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Shares").

     

     

    CUSIP No. 359616109SC 13G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      359616109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                  

       

     

    Item 4. OWNERSHIP:

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ý

     

     

    CUSIP No. 359616109SC 13G/APage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 359616109SC 13G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

     

     

    Get the next $FULC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FULC

    DatePrice TargetRatingAnalyst
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    9/12/2024$10.00 → $2.00Neutral → Underperform
    BofA Securities
    9/12/2024Buy → Hold
    Stifel
    More analyst ratings

    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hill Colin

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:09 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ezekowitz Alan

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:04 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Haviland Kate

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:14 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

    SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    8/12/25 9:01:04 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Fulcrum Therapeutics Inc.

    10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    7/29/25 8:39:01 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    7/29/25 8:34:24 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees an aggregate of 36,400

    8/8/25 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

    ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan-cellular increases in fetal hemoglobin (HbF); meaningful improvements in key markers of hemolysis and anemia; encouraging trends in vaso-occlusive crises (VOCs) ― ― On track to provide clinical data from the 20 mg dose cohort by the end of 2025 ― ― Ended Q2 2025 with $214.1 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., July 29, 2025 (GLOBE NEWSWI

    7/29/25 6:48:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fulcrum Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously

    7/29/25 11:36:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Fulcrum Therapeutics from Market Perform to Outperform and set a new price target of $12.00

    5/23/25 8:13:14 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Fulcrum Therapeutics from Neutral to Overweight and set a new price target of $10.00

    5/15/25 8:05:44 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Leadership Updates

    Live Leadership Updates

    View All

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

    3/18/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

    8/3/23 6:55:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/12/24 3:51:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VC

    7/28/25 4:01:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

    ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv

    5/1/25 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care